These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 19012104)
1. The effects of Diane-35 and metformin in treatment of polycystic ovary syndrome: an updated systematic review. Jing Z; Liang-Zhi X; Tai-Xiang W; Ying T; Yu-Jian J Gynecol Endocrinol; 2008 Oct; 24(10):590-600. PubMed ID: 19012104 [TBL] [Abstract][Full Text] [Related]
2. Metabolic profile of Diane-35 versus Diane-35 plus metformin in Chinese PCOS women under standardized life-style changes. Wu H; Ruan X; Jin J; Mueck AO Gynecol Endocrinol; 2015 Jul; 31(7):548-51. PubMed ID: 26004979 [TBL] [Abstract][Full Text] [Related]
3. Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with the polycystic ovary syndrome. Luque-Ramírez M; Alvarez-Blasco F; Botella-Carretero JI; Martínez-Bermejo E; Lasunción MA; Escobar-Morreale HF J Clin Endocrinol Metab; 2007 Jul; 92(7):2453-61. PubMed ID: 17426085 [TBL] [Abstract][Full Text] [Related]
4. Management of polycystic ovarian syndrome with Diane-35 or Diane-35 plus metformin. Feng W; Jia YY; Zhang DY; Shi HR Gynecol Endocrinol; 2016; 32(2):147-50. PubMed ID: 26507097 [TBL] [Abstract][Full Text] [Related]
5. Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. Morin-Papunen LC; Vauhkonen I; Koivunen RM; Ruokonen A; Martikainen HK; Tapanainen JS J Clin Endocrinol Metab; 2000 Sep; 85(9):3161-8. PubMed ID: 10999803 [TBL] [Abstract][Full Text] [Related]
6. [Effect of 6-month treatment with oral antiandrogen alone and in combination with insulin sensitizers on body composition, hormonal and metabolic parameters in women with polycystic ovary syndrome (PCOS) in order to determine therapeutic strategy]. Orbetsova M; Kamenov Z; Kolarov G; Zakharieva S; Khristov V; Atanasova I; Shigarminova R; Milcheva B; Genchev G Akush Ginekol (Sofiia); 2006; 45(7):16-28. PubMed ID: 17489164 [TBL] [Abstract][Full Text] [Related]
7. The platelet activating factor acetyl hydrolase, oxidized low-density lipoprotein, paraoxonase 1 and arylesterase levels in treated and untreated patients with polycystic ovary syndrome. Carlioglu A; Kaygusuz I; Karakurt F; Gumus II; Uysal A; Kasapoglu B; Armutcu F; Uysal S; Keskin EA; Koca C Arch Gynecol Obstet; 2014 Nov; 290(5):929-35. PubMed ID: 24840107 [TBL] [Abstract][Full Text] [Related]
8. Effect of Diane-35, alone or in combination with orlistat or metformin in Chinese polycystic ovary syndrome patients. Ruan X; Song J; Gu M; Wang L; Wang H; Mueck AO Arch Gynecol Obstet; 2018 Jun; 297(6):1557-1563. PubMed ID: 29602978 [TBL] [Abstract][Full Text] [Related]
9. Effects of an oral contraceptive containing cyproterone acetate (Diane-35) on the symptoms, hormone profile, and ovarian volume of hirsute women with polycystic ovarian syndrome. Prelević GM; Puzigaća Z; Balint-Perić LA Ann N Y Acad Sci; 1993 May; 687():255-62. PubMed ID: 8323181 [No Abstract] [Full Text] [Related]
10. Comparison of effects of 3 mg drospirenone plus 20 μg ethinyl estradiol alone or combined with metformin or cyproterone acetate on classic metabolic cardiovascular risk factors in nonobese women with polycystic ovary syndrome. Fruzzetti F; Perini D; Lazzarini V; Parrini D; Gambacciani M; Genazzani AR Fertil Steril; 2010 Oct; 94(5):1793-8. PubMed ID: 19931080 [TBL] [Abstract][Full Text] [Related]
11. Comparison of Diane 35 and Diane 35 plus finasteride in the treatment of hirsutism. Tartagni M; Schonauer LM; De Salvia MA; Cicinelli E; De Pergola G; D'Addario V Fertil Steril; 2000 Apr; 73(4):718-23. PubMed ID: 10731531 [TBL] [Abstract][Full Text] [Related]
12. Effects of metformin versus ethinyl-estradiol plus cyproterone acetate on ambulatory blood pressure monitoring and carotid intima media thickness in women with the polycystic ovary syndrome. Luque-Ramírez M; Mendieta-Azcona C; Alvarez-Blasco F; Escobar-Morreale HF Fertil Steril; 2009 Jun; 91(6):2527-36. PubMed ID: 18565522 [TBL] [Abstract][Full Text] [Related]
13. Effect of orlistat or metformin in overweight and obese polycystic ovary syndrome patients with insulin resistance. Song J; Ruan X; Gu M; Wang L; Wang H; Mueck AO Gynecol Endocrinol; 2018 May; 34(5):413-417. PubMed ID: 29172796 [TBL] [Abstract][Full Text] [Related]
14. Effects of an antiandrogenic oral contraceptive pill compared with metformin on blood coagulation tests and endothelial function in women with the polycystic ovary syndrome: influence of obesity and smoking. Luque-Ramírez M; Mendieta-Azcona C; del Rey Sánchez JM; Matíes M; Escobar-Morreale HF Eur J Endocrinol; 2009 Mar; 160(3):469-80. PubMed ID: 19139031 [TBL] [Abstract][Full Text] [Related]
15. Efficacy of Chinese patent medicine Tian Gui Capsule in patients with polycystic ovary syndrome: a randomized controlled trial. Kuek S; Wang WJ; Gui SQ Zhong Xi Yi Jie He Xue Bao; 2011 Sep; 9(9):965-72. PubMed ID: 21906521 [TBL] [Abstract][Full Text] [Related]
16. A comparative study to illustrate the benefits of using ethinyl estradiol-cyproterone acetate over metformin in patients with polycystic ovarian syndrome. Mhao NS; Al-Hilli AS; Hadi NR; Jamil DA; Al-Aubaidy HA Diabetes Metab Syndr; 2016; 10(1 Suppl 1):S95-8. PubMed ID: 26703220 [TBL] [Abstract][Full Text] [Related]
17. Effects of a low-dose estrogen-antiandrogen combination (Diane-35) on clinical signs of androgenization, hormone profile and ovarian size in patients with polycystic ovary syndrome. Prelević GM; Würzburger MI; Balint-Perić L; Puzigaća Z Gynecol Endocrinol; 1989 Dec; 3(4):269-80. PubMed ID: 2516704 [TBL] [Abstract][Full Text] [Related]
18. Is There An Advantage of Using Dingkun Pill () alone or in Combination with Diane-35 for Management of Polycystic Ovary Syndrome? A Randomized Controlled Trial. Deng Y; Wang YF; Zhu SY; Ma X; Xue W; Ma RL; Sun AJ Chin J Integr Med; 2020 Dec; 26(12):883-889. PubMed ID: 32915426 [TBL] [Abstract][Full Text] [Related]
19. How medical treatment affects mean platelet volume as a cardiovascular risk marker in polycystic ovary syndrome? Kabil Kucur S; Gozukara I; Aksoy A; Uludag EU; Keskin H; Kamalak Z; Carlioglu A Blood Coagul Fibrinolysis; 2015 Dec; 26(8):862-5. PubMed ID: 25402193 [TBL] [Abstract][Full Text] [Related]
20. [Combined use of metformin and Diane35 in polycystic ovary syndrome]. Mitkov M; Pekhlivanov B; Terzieva D Akush Ginekol (Sofiia); 2004; 43(3):34-7. PubMed ID: 15341255 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]